Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist

被引：0
|
作者：
Benjamin Berger
Jasper Dingemanse
Giancarlo Sabattini
Stéphane Delahaye
Urs Duthaler
Clemens Muehlan
Stephan Krähenbühl
机构：
[1] Idorsia Pharmaceuticals Ltd,Department of Clinical Pharmacology
[2] Idorsia Pharmaceuticals Ltd,Department of Preclinical Drug Metabolism and Pharmacokinetics
[3] University Hospital Basel,Division of Clinical Pharmacology and Toxicology
[4] University of Basel,Department of Biomedicine
来源：
Clinical Pharmacokinetics | 2021年 / 60卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1349 / 1360
页数：11
相关论文
共 50 条
  • [31] DARIDOREXANT, A DUAL OREXIN RECEPTOR ANTAGONIST, IMPROVES AGE-RELATED INSOMNIA IN RATS Abstracts
    Roch, Catherine
    Fischer, Cedric
    Jenck, Francois
    Steiner, Michel
    SLEEP, 2021, 44 : A1 - A1
  • [32] Daridorexant, a novel dual orexin receptor antagonist, delivers significant improvement in sleep parameters and daytime function for patients with insomnia disorder
    Roth, T.
    Zammit, G.
    Mignot, E.
    Leger, D.
    Bassetti, C.
    Pain, S.
    Kinter, D. Seboek
    JOURNAL OF SLEEP RESEARCH, 2020, 29 : 152 - 152
  • [33] Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease
    Boof, Marie-Laure
    Dingemanse, Jasper
    Brunke, Mareile
    Esselmann, Albert
    Heymer, Peter
    Kestermann, Olaf
    Lederer, Katharina
    Fietze, Ingo
    Ufer, Mike
    JOURNAL OF SLEEP RESEARCH, 2021, 30 (04)
  • [34] FIRST-IN-HUMAN STUDY OF ACT-541468, A NOVEL DUAL OREXIN RECEPTOR ANTAGONIST: CHARACTERIZATION OF ITS PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY
    Muehlan, C.
    Juif, P. -E.
    van Gerven, J.
    Heuberger, J.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S80 - S80
  • [35] Assessing the Abuse Potential of Daridorexant, an Investigational, New Dual Orexin Receptor Antagonist: Nonclinical Examinations in Rats
    Steiner, Michel
    Toeroek, Michael
    Giusepponi, Maria Elena
    Tessari, Michela
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 387 - 388
  • [36] Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
    Han, Andrew H.
    Burroughs, Caroline R.
    Falgoust, Evan P.
    Hasoon, Jamal
    Hunt, Grace
    Kakazu, Juyeon
    Lee, Tim
    Kaye, Adam M.
    Kaye, Alan D.
    Ganti, Latha
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (05):
  • [37] DARIDOREXANT: A DUAL, EQUIPOTENT, AND INSURMOUNTABLE ANTAGONIST OF BOTH OREXIN-1 AND OREXIN-2 RECEPTORS
    Grandjean, Celia Mueller
    Kiry, Manon
    Vaillant, Catherine
    Nayler, Oliver
    Gatfield, John
    SLEEP, 2021, 44 : A25 - A25
  • [38] Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
    van Giersbergen, PLM
    Popescu, G
    Bodin, F
    Dingemanse, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (01): : 15 - 22
  • [39] SIMULATED DRIVING PERFORMANCE AFTER BEDTIME ADMINISTRATION OF DARIDOREXANT, A DUAL OREXIN RECEPTOR ANTAGONIST FOR THE TREATMENT OF INSOMNIA.
    Muehlan, C.
    Brooks, S.
    Vaillant, C.
    Meinel, M.
    Jacobs, G.
    Zuiker, R.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S37 - S38
  • [40] Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder (vol 87, pg 347, 2020)
    Dauvilliers, Yves
    Zammit, Gary
    Fietze, Ingo
    Mayleben, David
    Kinter, Dalma Seboek
    Pain, Scott
    Hedner, Jan
    ANNALS OF NEUROLOGY, 2020, 88 (03) : 647 - 651
12345